panel lungcarta massarray iplex genotyping (agena bioscience)
agena bioscience is a verified supplier 
agena bioscience manufactures this product 
90
Structured Review
agena bioscience
panel lungcarta massarray iplex genotyping
Panel Lungcarta Massarray Iplex Genotyping, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+lungcarta+panel/panel+lungcarta++++massarray+iplex+genotyping/pm30149144-48-12-21
Average 90 stars, based on 1 article reviews
Panel Lungcarta Massarray Iplex Genotyping, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+lungcarta+panel/panel+lungcarta++++massarray+iplex+genotyping/pm30149144-48-12-21
Average 90 stars, based on 1 article reviews
panel lungcarta massarray iplex genotyping - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Gene Expression:Article Title: MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Article Snippet: Oncotarget42436www.impactjournals.com/oncotarget Molecular screening for other gene sequence abnormalities For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Article Title: c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. Article Snippet: Mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Isolation:Article Title: MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Article Snippet: Oncotarget42436www.impactjournals.com/oncotarget Molecular screening for other gene sequence abnormalities For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Article Title: c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. Article Snippet: Mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Formalin-fixed Paraffin-Embedded:Article Title: MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Article Snippet: Oncotarget42436www.impactjournals.com/oncotarget Molecular screening for other gene sequence abnormalities For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Article Title: c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. Article Snippet: Mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Expressing:Article Title: MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Article Snippet: Oncotarget42436www.impactjournals.com/oncotarget Molecular screening for other gene sequence abnormalities For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Article Title: c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. Article Snippet: Mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Staining:Article Title: MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Article Snippet: Oncotarget42436www.impactjournals.com/oncotarget Molecular screening for other gene sequence abnormalities For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Article Title: c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. Article Snippet: Mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Multiplex Assay:Article Title: MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Article Snippet: Oncotarget42436www.impactjournals.com/oncotarget Molecular screening for other gene sequence abnormalities For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Article Title: c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. Article Snippet: Mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Electrophoresis:Article Title: MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Article Snippet: Oncotarget42436www.impactjournals.com/oncotarget Molecular screening for other gene sequence abnormalities For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Article Title: c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. Article Snippet: Mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Sequencing:Article Title: MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Article Snippet: Oncotarget42436www.impactjournals.com/oncotarget Molecular screening for other gene sequence abnormalities For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Article Title: c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. Article Snippet: Mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Mass Spectrometry:Article Title: MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Article Snippet: Oncotarget42436www.impactjournals.com/oncotarget Molecular screening for other gene sequence abnormalities For the SC cohort, mass spectrometry was used to test 214 mutations affecting 26 oncogenes and Article Title: c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. Article Snippet: Mass spectrometry was used to test 214 mutations affecting 26 oncogenes and |